OTTAWA, June 2 /CNW Telbec/ - PharmaGap Inc. (TSX-V: GAP) (“PharmaGap” or “the Company”) released today additional results of animal studies indicating effectiveness of its lead cancer drug, PhG-alpha-1, in treating two types of highly aggressive human colon cancer. These results are consistent with and augment earlier results using breast and colon cancers announced by the Company on April 17, 2008.
